Equities research analysts at Oppenheimer initiated coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) in a research report issued on Monday. The brokerage set an “outperform” rating and a $28.00 price target on the stock. Oppenheimer’s price target would suggest a potential upside of 20.40% from the company’s current price.
A number of other brokerages also recently commented on NRIX. Jefferies Financial Group boosted their target price on Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, June 8th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Tuesday, April 21st. Truist Financial increased their price objective on Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Finally, Robert W. Baird increased their target price on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $32.20.
Read Our Latest Research Report on Nurix Therapeutics
Nurix Therapeutics Stock Performance
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last released its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.03). The company had revenue of $6.25 million during the quarter, compared to analyst estimates of $14.25 million. Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. Sell-side analysts forecast that Nurix Therapeutics will post -2.88 earnings per share for the current fiscal year.
Insider Activity
In other news, CFO Houte Hans Van sold 14,055 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the completion of the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. This represents a 27.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 5,394 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00. Following the completion of the sale, the insider owned 115,005 shares of the company’s stock, valued at approximately $2,300,100. The trade was a 4.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 25,051 shares of company stock worth $434,466. Insiders own 6.70% of the company’s stock.
Institutional Trading of Nurix Therapeutics
Institutional investors have recently modified their holdings of the company. Larson Financial Group LLC increased its position in shares of Nurix Therapeutics by 339.0% during the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after purchasing an additional 1,190 shares during the period. California State Teachers Retirement System lifted its position in Nurix Therapeutics by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock worth $1,290,000 after purchasing an additional 1,476 shares during the period. Intesa Sanpaolo Wealth Management bought a new position in Nurix Therapeutics in the fourth quarter worth $31,000. Royal Bank of Canada boosted its stake in Nurix Therapeutics by 17.6% during the fourth quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock worth $206,000 after buying an additional 1,623 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in Nurix Therapeutics by 8.2% during the fourth quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after buying an additional 1,674 shares in the last quarter.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company’s pipeline includes multiple programs in various stages of development.
Read More
- Five stocks we like better than Nurix Therapeutics
- JPMorgan Stands by Sky-High Broadcom Target as Shares Slide
- 5 Places Investors Can Hide If the AI Trade Keeps Cracking
- Is Apple’s Latest Plunge the Canary in the Coal Mine for Tech Stocks?
- New Stock Price Highs Are on the Menu for Darden Restaurants
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-EGX.png){kind=small}
